Pharmaceuticals,Pharmaceuticals sector projects by Strides Arcolab Limited in
Project Information
4795
Strides Arcolab Limited
Pfenex Inc. And Agila Biotech Private Limited, A Subsidiary Of Strides Arcolab Limited Have Entered Into A Joint Venture To Develop, Manufacture And Commercialize An Initial Pipeline Of Six Biosimilar Products For The Global Market. As A JV Both Parties Will Equally Share In Decision Making Regarding Product Development And Commercialization, Agila Biotech Will Be A 51% Equity Stakeholder. The Lead Product For The Joint Venture Is Interferon Beta-1b, A Biosimilar To Betaseron®, Indicated For Relapsing-Remitting And Secondary-Progressive Forms Of Multiple Sclerosis, Commencing Human Clinical Trials By Q4 2013. According To Contract Pfenex Will Assume Primary Responsibility For Development Of An Optimized Production Strain, Process And Analytical Package For Each Product, While Agila Biotech Will Be Responsible For Pre-Clinical And Phase 1 Development, As Well As Cgmp Manufacturing. The Joint Venture Will Then Progress The Products Through Phase 3 And Into Commercialization. Agila Biotech Private Limited, India Is A Wholly Owned Subsidiary Of Strides Acrolab Limited (Strides).
Project Value
Refer document
JV Agreement Signed
Not Specified
India
Pharmaceuticals,Pharmaceuticals
Disclaimer :
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
